FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

The global cell culture market is projected to grow at a CAGR of 12% from 2025 to 2030. This growth is driven by increasing ...

The pharmaceutical manufacturing equipment market is projected to grow at a CAGR of 6-8% during the forecast period. Growth ...

LOTTE BIOLOGICS (CEO James Park) announced on April 24 (KST) that it has signed a manufacturing agreement with an Asia-based biotech company for the production of a clinical-stage ADC candidate. This ...

FujiFilm Diosynth plans to produce Regeneron's biologic medicines over 10 years in its Holly Springs facility, which is scheduled to begin operations this year.

Ahead of its scheduled opening later this year, the massive Fujifilm Diosynth Biotechnologies manufacturing plant in Holly ...

Agreement secures additional U.S. manufacturing capacity to help ensure patient access to medicineHOLLY SPRINGS, N.C., April 23, 2025 -- ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer ...

Co-organized by the Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO), BIO ...